会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 64. 再颁专利
    • Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
    • 苯乙胺和稠环变体作为儿茶酚胺的前药,及其用途
    • USRE42802E1
    • 2011-10-04
    • US11790465
    • 2007-04-25
    • Hâkan Vilheim WikströmDurk DijkstraBastiaan Johan Venhuis
    • Hâkan Vilheim WikströmDurk DijkstraBastiaan Johan Venhuis
    • A61K31/45C07D221/06C07D219/06
    • C07D221/14C07C225/14C07C225/20C07C2601/16C07C2603/26C07D211/32C07D211/70C07D221/08C07D221/10C07D221/18
    • Compounds of the general formula I wherein rings B, C, D and E may be present or not and, when present, are combined with A as A+C, A+E, A+B+C, A+B+D, A+B+E, A+C+E, A+B+C+D or A+B+C+D+E, rings B, C and E being aliphatic whereas ring D may be aliphatic or aromatic/heteroaromatic, and wherein X is —(CH2)m—, in which m is an integer 1-3, to form a ring E or, when E is absent, a group R1 bound to the nitrogen atom, wherein R1 is selected from the group consisting of a hydrogen atom, alkyl or haloalkyl groups of 1 to 3 carbon atoms, cycloalkyl(alkyl) groups of 3 to 5 carbon atoms (i.e. including cyclopropyl, cyclopropylmethyl, cyclobutyl and cyclobutylmethyl) and wherein Y is —(CH2)n—, in which n is an integer 1-3, to form a ring C or when C is absent, a group R2 bound to the nitrogen atom, wherein R2 is selected from the group consisting of a hydrogen atom, alkyl or haloalkyl groups of 1 to 7 carbon atoms, cycloalkyl(alkyl) groups of 3 to 7 carbon atoms, alkenyl or alkylnyl groups of 3 to 6 carbon atoms, arylalkyl, heteroarylalkyl having 1 to 3 carbon atoms in the alkyl moiety, whilst the aryl/heteroaryl nucleus may be substituted, provided that when rings B, C, D and E are absent NR1R2 is different from dimethylamino, N-methyl-N-ethylamino, N-methyl-N-propynyl-amino, N-methyl-N-propylamino and N-hydroxipropyl-N-methylamino, and salts thereof with pharmaceutically acceptable acids or bases are disclosed as well as the use of such compounds for the manufacturing of pharmaceutical compositions for the treatment of Parkinson's disease, psychoses, Huntington's disease, impotence, renal failure, heart failure or hypertension, such pharmaceutical compositions and methods of treating Parkinson's disease and schizophrenia.
    • 其中环B,C,D和E可以存在或不存在,并且当存在时与A组合为A + C,A + E,A + B + C,A + B + D, A + B + E,A + C + E,A + B + C + D或A + B + C + D + E,环B,C和E为脂族环,而环D可为脂族或芳族/杂芳族, 其中X是 - (CH 2)m - ,其中m是整数1-3,以形成环E,或当E不存在时,与氮原子结合的基团R1,其中R1选自 具有1-3个碳原子的氢原子,烷基或卤代烷基,3至5个碳原子的环烷基(烷基)(即包括环丙基,环丙基甲基,环丁基和环丁基甲基),其中Y是 - (CH 2)n - ,其中 n为整数1-3,形成环C或当不存在C时,与氮原子结合的基团R 2选自氢原子,碳原子数为1〜7的烷基或卤代烷基 3〜7个碳原子的原子,环烷基(烷基),烯基或烷基 3至6个碳原子,芳基烷基,烷基部分具有1至3个碳原子的杂芳基烷基,而芳基/杂芳基核可以被取代,条件是当环B,C,D和E不存在时,NR 1 R 2不同于二甲基氨基, N-甲基-N-乙基氨基,N-甲基-N-丙炔基 - 氨基,N-甲基-N-丙基氨基和N-羟基丙基-N-甲基氨基及其与药学上可接受的酸或碱的盐以及其用途 的这种化合物用于制备用于治疗帕金森病,精神病,亨廷顿氏病,阳ence,肾衰竭,心力衰竭或高血压的药物组合物,用于治疗帕金森病和精神分裂症的药物组合物和方法。
    • 66. 发明授权
    • Pro-fragrances
    • 亲香料
    • US06551987B1
    • 2003-04-22
    • US10030758
    • 2001-10-22
    • Gregory Scott MiracleLon Montgomery Gray
    • Gregory Scott MiracleLon Montgomery Gray
    • A61K746
    • A61Q13/00A61K8/41A61K2800/57C07C225/14C07C225/20C07C255/14C07C2601/08C07C2601/16C11D3/507
    • The present invention relates to fragrance delivery systems which comprise: a) one or more pro-fragrances having formula (I) wherein G1 and G2 are methyl, or a cyclic hydrocarbyl unit derived from the isomers of ionone and/or damascone; R and R1 are each independently C1-C22 substituted or unsubstituted, branched or unbranched alkyl, C2-C22 substituted or unsubstituted, branched or unbranched alkenyl, C2-C20 substituted or unsubstituted, branched or unbranched hydroxyalkyl, C7-C20 substituted or unsubstituted alkylenearyl, C3-C20 substituted or unsubstituted cycloalkyl, alkyleneoxy, C6-C20 aryl, C5-C20 heteroaryl comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, sulfur, and mixtures thereof; two of the units Y1, Y2, R or R1 can be taken together to form one or more aromatic or non-aromatic, heterocyclic or non-heterocyclic, single rings, fused rings, bicyclo rings, spiroannulated rings, or mixtures thereof, said rings comprising from 3 to 20 carbon atoms and one or more heteroatoms selected from the group consisting of nitrogen, oxygen, sulfur, and mixtures thereof; b) one or more aldehyde releasing oxazolidine pro-fragrances; and c) the balance carriers, pro-fragrances, pro-accords, other perfume ingredients.
    • 本发明涉及香料递送系统,其包括:a)一种或多种具有其中G1和G2是甲基的式(I)的一种或多种亲香料或衍生自紫罗酮和/或大蠊的异构体的环状烃基单元; R和R 1各自独立地为C 1 -C 22取代或未取代的支链或非支链烷基,C2-C22取代或未取代的支链或非支链烯基,C2-C20取代或未取代的支链或非支链羟烷基,C7-C20取代或未取代的亚烷基硬脂基, C 3 -C 20取代或未取代的环烷基,亚烷氧基,C 6 -C 20芳基,C 5 -C 20杂芳基,其包含一个或多个选自氮,氧,硫及其混合物的杂原子; 两个单元Y 1,Y 2,R或R ​​1可以一起形成一个或多个芳族或非芳族,杂环或非杂环单环,稠合环,双环,螺环或其混合物,所述环 包含3至20个碳原子和一个或多个选自氮,氧,硫及其混合物的杂原子; b)一种或多种醛释放恶唑烷亲香料; 和c)平衡载体,亲香料,亲和剂,其他香料成分。
    • 68. 发明授权
    • Process for the production of a chromogenically developed color
photographic image using a compound capable of reacting with primary
aromatic amines
    • 使用能够与伯芳香胺反应的化合物生产显色显影的彩色照相图像的方法
    • US5731133A
    • 1998-03-24
    • US647640
    • 1996-05-15
    • Thomas HubschArno Schmuck
    • Thomas HubschArno Schmuck
    • G03C7/00C07C225/12C07C225/14C07C225/20C07C229/12C07C229/30C07C229/34C07C233/31C07C255/30C07D295/104C07D295/145G03C7/392G03C7/407G03C7/42G03C11/00
    • C07D295/104C07C225/12C07C225/14C07C225/20C07C229/12C07C229/30C07C229/34C07C233/31C07C255/30C07D295/145G03C7/39208G03C7/407C07C2101/14C07C2101/16
    • The storage stability of photographic color images obtained by chromogenic development may be improved by compounds of the formula I, which are capable of reacting with primary amines, in particular color developer compounds (reagent for primary amines). The compounds of the formula may be added to the color photographic recording material or to a treatment bath downstream from color development. Compounds of the formula I are moreover suitable as an additive to a spent photographic processing bath or its overflow in order to reduce therein the content of color developer compounds before the processing bath or the overflow is disposed of or regenerated for further use. ##STR1## In formula I: A means --OR.sup.2, --SR.sup.2 or --NR.sup.2 R.sup.3 ; R.sup.1 means H, alkyl, aryl, acyl, sulphonyl or a residue as in A or a residue which, together with A or together with Z.sup.1, completes a ring;R.sup.2 means H, alkyl, aryl, acyl, sulphonyl; R.sup.3 means a residue as in R.sup.2 or optionally a residue which, together with R.sup.2 and the N atom, forms a heterocyclic ring, Z.sup.1 and Z.sup.2 mutually independently mean: H, halogen, cyano, alkyl, aryl, acyl, a heterocyclic group, alkoxycarbonyl, aroxycarbonyl, sulphonyl, imino, imido, sulphamoyl, carbonamido or sulphonamido; wherein Z.sup.1 and Z.sup.2, together with the C atom to which they are attached, may form a carbocyclic or heterocyclic ring system.
    • 通过显影发展获得的照相彩色图像的储存稳定性可以通过能够与伯胺反应的式I化合物,特别是彩色显影剂化合物(伯胺试剂)来改善。 可以将该配方化合物加入到彩色照相记录材料中,或加入到显影下游的处理浴中。 此外,式I化合物适合作为用过的照相处理槽或其溢流剂的添加剂,以便在处理槽或溢出处理或再生以供进一步使用之前将其中的显色剂化合物的含量减少。 (I)式Ⅰ中,A表示-OR2,-SR2或-NR2R3; R1表示H中的H,烷基,芳基,酰基,磺酰基或残基,或与A或与Z1一起形成环的残基; R2表示H,烷基,芳基,酰基,磺酰基; R3表示残基,如R2或任选残基,其与R2和N原子一起形成杂环,Z1和Z2相互独立地表示:H,卤素,氰基,烷基,芳基,酰基,杂环基,烷氧基羰基 ,芳氧基羰基,磺酰基,亚氨基,亚氨基,氨磺酰基,碳酰氨基或磺酰氨基; 其中Z1和Z2与它们所连接的C原子一起可以形成碳环或杂环系。
    • 70. 发明授权
    • Method of treating inflammation and pain with
2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones,
2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and
derivatives thereof
    • 用2-(N-取代 - 氨基烷基)-5-(E) - 亚烷基环戊酮,2-(N-取代 - 氨基烷基)-5-(E) - 芳基亚烷基环戊酮及其衍生物治疗炎症和疼痛的方法
    • US5281622A
    • 1994-01-25
    • US44983
    • 1993-04-08
    • Lan K. WongHai-Tao ChenZhi-Zhong Ji
    • Lan K. WongHai-Tao ChenZhi-Zhong Ji
    • A61K31/13C07C225/14C07C225/18C07D295/116A61K31/12A61K31/265A61K31/36
    • C07D295/116A61K31/13C07C225/14C07C225/18C07C2101/08C07C2101/10
    • Novel 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones, 2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and derivatives thereof having the formula ##STR1## wherein x is methylene or ethylene; R.sub.1 is dimethylamino, diethylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, anilino or substituted anilino; R.sub.2 is hydrogen, straight or branched alkyl of 1 to 9 carbon atoms, aryl or arylalkyl; R.sub.3 is hydrogen, straight or branched alkyl of 1 to 9 carbon atoms, aryl or arylalkyl; and R.sub.4 is hydrogen, methyl, ethyl, allyl, benzyl, substituted benzyl, cyclopentyl, substituted cyclopentyl, cyclopenten-1-yl, or substituted cyclopenten-1-yl; and wherein aryl is phenyl or phenyl substituted with one or more methoxyl, hydroxyl, methylenedioxy, chloro, bromo, fluoro, ethoxycarbonylmethoxy, benzoxy, alkyl group, or their combination, possess anti-inflammatory, analgesic and anticancer properties. The methods of using these compounds to treat inflammation, pain and cancer in mammals and to resist or substantially prevent inflammation and pain in mammals are also disclosed.
    • 新的2-(N-取代 - 氨基烷基)-5-(E) - 亚烷基环戊酮,2-(N-取代 - 氨基烷基)-5-(E) - 芳基亚烷基环戊酮及其衍生物具有下式(*化学结构* )其中x是亚甲基或亚乙基; R1是二甲基氨基,二乙基氨基,1-吡咯烷基,1-哌啶基,4-吗啉基,苯胺基或取代的苯胺基; R2是氢,1至9个碳原子的直链或支链烷基,芳基或芳基烷基; R3是氢,1至9个碳原子的直链或支链烷基,芳基或芳基烷基; R 4是氢,甲基,乙基,烯丙基,苄基,取代的苄基,环戊基,取代的环戊基,环戊烯-1-基或取代的环戊烯-1-基; 羟基,亚甲二氧基,氯,溴,氟,乙氧羰基甲氧基,苯氧基,烷基或它们的组合取代的苯基或苯基被苯基取代,具有抗炎,镇痛和抗癌特性。 还公开了使用这些化合物治疗哺乳动物中的炎症,疼痛和癌症并抵抗或基本上预防哺乳动物的炎症和疼痛的方法。